[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05480644":3,"trial-entities:NCT05480644":81,"trial-summary:NCT05480644":86},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":24,"interventions":27,"primary_outcomes":28,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":22,"healthy_volunteers":14,"eligibility_criteria":36,"std_ages":42,"locations":45,"central_contacts":71,"overall_officials":76,"references":79,"see_also_links":80},"NCT05480644","Pro00110602","Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors","RECRUITING","2032-12","2025-11","2025-11-19","2022-12-01","Duke University","OTHER",false,"The purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the Department of Radiation Oncology at Duke Cancer Center.","Repository blood samples will be used to study the association of circulating biomarkers with radiation therapy outcomes.",[18,19],"Brain Tumor, Primary","Brain Metastases, Adult",[],"OBSERVATIONAL",null,[],{"count":25,"type":26},300,"ESTIMATED",[],[29],{"measure":30,"description":31,"timeFrame":32},"Number of circulating immune cells in peripheral blood","reported as mean +\u002F- standard deviation","6 weeks post radiation therapy",[],"ALL","18 Years",{"inclusion":37,"exclusion":39,"raw_text":41},[38],"Have a confirmed diagnosis of primary or metastatic brain tumor (histology or imaging as appropriate)",[40],"None","Inclusion Criteria:\n\n* Have a confirmed diagnosis of primary or metastatic brain tumor (histology or imaging as appropriate)\n\nExclusion Criteria:\n\n* None",[43,44],"ADULT","OLDER_ADULT",[46],{"facility":47,"status":7,"city":48,"state":49,"zip":50,"country":51,"contacts":52,"geoPoint":68},"Duke Cancer Center","Durham","North Carolina","27710","United States",[53,58,61,64,66],{"name":54,"role":55,"phone":56,"email":57},"Kaitlin Bailey, RN","CONTACT","919-668-3726","Kaitlin.Bailey@duke.edu",{"name":59,"role":55,"email":60},"Linda Kaltenbach, PhD","Linda.Kaltenbach@duke.edu",{"name":62,"role":63},"Eugene Vaios, MD MBA","PRINCIPAL_INVESTIGATOR",{"name":65,"role":63},"Zach Reitman, MD PhD",{"name":67,"role":63},"Scott Flody, MD PhD",{"lat":69,"lon":70},35.99403,-78.89862,[72,75],{"name":73,"role":55,"phone":74,"email":57},"Kaitlin Bailey, RN OCN","(919) 668-3726",{"name":59,"role":55,"email":60},[77],{"name":62,"affiliation":78,"role":63},"Duke University Health System (DUHS)",[],[],{"nct_id":4,"conditions":82,"biomarkers":85},[83,84],"Brain Neoplasm","Metastatic Malignant Neoplasm in the Brain",[],{"nct_id":4,"found":87,"summary":88,"prompt_version":98},true,{"design":89,"status":90,"heading":91,"summary":92,"follow_up":93,"word_count":94,"commitments":95,"compensation":96,"drugs_mentioned":97},"This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to include 300 participants.","completed","Repository for Brain Tumor Biomarkers","This study is collecting blood samples from adults with primary or metastatic brain tumors who are receiving radiation therapy at Duke Cancer Center. The goal is to create a collection (repository) of these samples to help researchers understand how certain substances in the blood (circulating biomarkers) are connected to how well radiation therapy works. There are no specific interventions or drugs being tested in this study. You can join if you are 18 years or older and have a confirmed diagnosis of a primary or metastatic brain tumor. The study aims to enroll 300 participants. The main thing they will measure is the number of immune cells in your blood six weeks after you finish radiation therapy. The current recruitment status is unclear.","Researchers will measure circulating immune cells in your blood 6 weeks after radiation therapy.",123,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]